Summary: In this issue, Waarts and colleagues developed an advanced ex vivo CRISPR screening platform to identify vulnerabilities in clonal hematopoiesis (CH). This unique system allowed the authors to identify a link between IDH2 and TET2 CH mutations, histone demethylases, and altered cytokine signaling, which enabled targeting by ruxolitinib leading to the elimination of CH clones, offering a possible path for preventing the development of malignancy. See related article by Waarts et al., p. 1860

中文翻译：

---

Ruxolitinib 能否破坏 TET2 和 IDH2 驱动的克隆造血？


摘要： 在本期中，Waarts及其同事开发了一种先进的离体CRISPR筛选平台，以识别克隆性造血（CH）的脆弱性。这种独特的系统使作者能够识别 IDH2 和 TET2 CH 突变、组蛋白去甲基化酶和改变的细胞因子信号之间的联系，这使得 ruxolitinib 的靶向能够消除 CH 克隆，为预防恶性肿瘤的发展提供了一条可能的途径。参见 Waarts 等人的相关文章，第 1860 页